Note 14: Mezzanine Equity

Series S Preferred Stock

On December 28, 2022 the Company acquired Soin Therapeutics by way of merger. In connection with this transaction, with a potential value of up to $30 million, the Company tendered 100,000 shares of the Company's Series S Convertible Preferred Stock. Shares of Series S Convertible Preferred Stock are convertible into the Company’s common shares at a ratio of 1:1. As of April 1, 2023 and December 31, 2022, there were 100,000 shares of Series S Convertible Preferred Stock outstanding.